News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Withdraws Bid For EU Regulatory OK Of Asthma Medicine
November 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Merck & Co. (MRK) has withdrawn its application for European regulatory approval of an asthma treatment, citing outstanding questions by regulators.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Merck & Co.
MORE ON THIS TOPIC
FDA
7 FDA decisions to watch for in Q3
July 2, 2026
·
7 min read
·
Tristan Manalac
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
July 2, 2026
·
2 min read
·
Tristan Manalac
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
